Compare · AZTR vs LLY
AZTR vs LLY
Side-by-side comparison of Azitra Inc (AZTR) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZTR and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.21T, about 221215.4x AZTR ($5.5M).
- Over the past year, AZTR is down 87.0% and LLY is up 62.6% - LLY leads by 149.6 points.
- LLY has been more active in the news (26 items in the past 4 weeks vs 6 for AZTR).
- LLY has more recent analyst coverage (25 ratings vs 0 for AZTR).
- Company
- Azitra Inc
- Eli Lilly and Company
- Price
- $0.75-16.58%
- $1373.46+6.41%
- Market cap
- $5.5M
- $1.21T
- 1M return
- -44.37%
- +18.46%
- 1Y return
- -86.98%
- +62.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2023
- News (4w)
- 6
- 26
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest AZTR
- SEC Form 8-K filed by Azitra Inc
- Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
- SEC Form 8-K filed by Azitra Inc
- Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
- SEC Form 8-K filed by Azitra Inc
- Azitra, Inc. Announces Reverse Stock Split
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
- Azitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Azitra Inc
Latest LLY
- SEC Form 10-Q filed by Eli Lilly and Company
- SEC Form 8-K filed by Eli Lilly and Company
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Lilly declares fourth-quarter 2026 dividend
- Gabelli To Host 8th Annual Healthcare Symposium
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026